{
    "nct_id": "NCT05232916",
    "official_title": "A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)",
    "inclusion_criteria": "* HLA-A*02-positive, unless being enrolled in the third non-HLA-A*02 arm\n* Histologically confirmed diagnosis of HER2/neu positive primary breast cancer for all tumors biopsied (multifocal, multicentric, or synchronous contralateral disease)\n* Completion of both neoadjuvant and adjuvant trastuzumab-based standard of care breast cancer therapy\n* Stage I, II, or III at presentation with pathologic evidence of residual invasive carcinoma in the breast or axillary lymph nodes (residual disease) at surgery following completion of neoadjuvant therapy -OR- Stage III at presentation with pathologic complete response (pCR) at surgery following completion of neoadjuvant therapy\n* The subject can begin study therapy within one year of completion of adjuvant trastuzumab-based therapy and any other standard therapies, but, study therapy can be administered concurrently with endocrine therapy.\n* No clinical evidence of residual or persistent breast cancer per treating physician assessment\n* ECOG 0-2\n* Adequate organ function\n* Negative pregnancy test or evidence of post-menopausal status\n* If of childbearing potential, willing to use a form of highly effective contraception\n* Subject must both reside in and have been treated for their cancer in the country in which the clinical site is located.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Stage IV cancer or metastatic breast cancer at any time\n* Inflammatory breast cancer\n* Receiving other investigational agents\n* Receiving chemotherapy\n* Requiring long-term systemic treatment with corticosteroids or other immunosuppressive therapy\n* History of immunodeficiency or active autoimmune disease\n* A history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony-stimulating factors such as sargramostim, yeast-derived products, or any component of the investigational product\n* Other malignancies except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin\n* Active infection\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.",
    "miscellaneous_criteria": ""
}